Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E-β-thalassemia): a single center study from eastern India. (öffnet neues Fenster)

Bohara VV, Ray S, Chakrabarti P, Ray SS, Nath UK, Chaudhuri U.

Quelle‎: Hemoglobin 2014;38(1):44-8.

Indiziert‎: PubMed 24144212

DOI‎: 10.3109/03630269.2013.845844

https://www.ncbi.nlm.nih.gov/pubmed/24144212 (öffnet neues Fenster)

Hydroxyurea in thalassemia intermedia--a promising therapy. (öffnet neues Fenster)

Dixit A, Chatterjee TC, Mishra P, Choudhry DR, Mahapatra M, Tyagi S, Kabra M, Saxena R, Choudhry VP.

Quelle‎: Ann Hematol 2005;84(7):441-6.

Indiziert‎: PubMed 15838670

DOI‎: 10.1007/s00277-005-1026-4

https://www.ncbi.nlm.nih.gov/pubmed/15838670 (öffnet neues Fenster)

Effect of hydroxyurea on the transfusion requirements in patients with severe HbE-beta-thalassaemia: a genotypic and phenotypic study. (öffnet neues Fenster)

Italia KY, Jijina FF, Merchant R, Panjwani S, Nadkarni AH, Sawant PM, Nair SB, Ghosh K, Colah RB.

Quelle‎: J Clin Pathol 2010;63(2):147-50.

Indiziert‎: PubMed 20154037

DOI‎: 10.1136/jcp.2009.070391

https://www.ncbi.nlm.nih.gov/pubmed/20154037 (öffnet neues Fenster)

Echocardiographic finding in beta-thalassemia intermedia and major: absence of pulmonary hypertension following hydroxyurea treatment in beta-thalassemia intermedia. (öffnet neues Fenster)

Karimi M, Borzouee M, Mehrabani A, Cohan N.

Quelle‎: Eur J Haematol 2009;82(3):213-8.

Indiziert‎: PubMed 19077048

DOI‎: 10.1111/j.1600-0609.2008.01192.x

https://www.ncbi.nlm.nih.gov/pubmed/19077048 (öffnet neues Fenster)

Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. (öffnet neues Fenster)

Karimi M, Mohammadi F, Behmanesh F, Samani SM, Borzouee M, Amoozgar H, Haghpanah S.

Quelle‎: Eur J Haematol 2010;84(1):52-8.

Indiziert‎: PubMed 19799627

DOI‎: 10.1111/j.1600-0609.2009.01356.x

https://www.ncbi.nlm.nih.gov/pubmed/19799627 (öffnet neues Fenster)

Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece. (öffnet neues Fenster)

Loukopoulos D, Voskaridou E, Kalotychou V, Schina M, Loutradi A, Theodoropoulos I.

Quelle‎: Blood Cells Mol Dis 2000;26(5):453-66.

Indiziert‎: PubMed 11112383

DOI‎: 10.1006/bcmd.2000.0328

https://www.ncbi.nlm.nih.gov/pubmed/11112383 (öffnet neues Fenster)

Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. (öffnet neues Fenster)

Perrine SP.

Quelle‎: Pediatr Ann 2008;37(5):339-46.

Indiziert‎: PubMed 18543545

https://www.ncbi.nlm.nih.gov/pubmed/18543545 (öffnet neues Fenster)

Single and combination drug therapy for fetal hemoglobin augmentation in hemoglobin E-beta 0-thalassemia: Considerations for treatment. (öffnet neues Fenster)

Singer ST, Kuypers FA, Olivieri NF, Weatherall DJ, Mignacca R, Coates TD, Davies S, Sweeters N, Vichinsky EP.

Quelle‎: Ann N Y Acad Sci 2005;1054:250-6.

Indiziert‎: PubMed 16339672

DOI‎: 10.1196/annals.1345.031

https://www.ncbi.nlm.nih.gov/pubmed/16339672 (öffnet neues Fenster)

Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules. (öffnet neues Fenster)

Chaidos A, Makis A, Hatzimichael E, Tsiara S, Gouva M, Tzouvara E, Bourantas KL.

Quelle‎: Acta Haematol 2004;111(4):189-95.

Indiziert‎: PubMed 15153710

DOI‎: 10.1159/000077551

https://www.ncbi.nlm.nih.gov/pubmed/15153710 (öffnet neues Fenster)

Efficacy of erythropoietin on dialysis in patients with beta thalassemia minor. (öffnet neues Fenster)

Di Iorio B, De Nicola L, Bellizzi V, Minutolo R, Zamboli P, Rubino R, Fuiano G, Conte G.

Quelle‎: Blood Purif 2004;22(5):453-60.

Indiziert‎: PubMed 15359104

DOI‎: 10.1159/000080729

https://www.ncbi.nlm.nih.gov/pubmed/15359104 (öffnet neues Fenster)

The role of recombinant human erythropoietin in the treatment of thalassemia. (öffnet neues Fenster)

Rachmilewitz EA, Aker M.

Quelle‎: Ann N Y Acad Sci 1998;850:129-38.

Indiziert‎: PubMed 9668535

https://www.ncbi.nlm.nih.gov/pubmed/9668535 (öffnet neues Fenster)

Darbepoetin alfa for the treatment of anaemia in alpha- or beta- thalassaemia intermedia syndromes. (öffnet neues Fenster)

Singer ST, Vichinsky EP, Sweeters N, Rachmilewitz E.

Quelle‎: Br J Haematol 2011;154(2):281-4.

Indiziert‎: PubMed 21496003

DOI‎: 10.1111/j.1365-2141.2011.08617.x

https://www.ncbi.nlm.nih.gov/pubmed/21496003 (öffnet neues Fenster)

The emerging role of fetal hemoglobin induction in non-transfusion-dependent thalassemia. (öffnet neues Fenster)

Thein SL.

Quelle‎: Blood Rev 2012;26 Suppl 1:S35-9.

Indiziert‎: PubMed 22631042

DOI‎: 10.1016/S0268-960X(12)70011-5

https://www.ncbi.nlm.nih.gov/pubmed/22631042 (öffnet neues Fenster)